XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.16

-3.2%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Olu Emuleomo who started this subject	10/31/2003 9:21:25 AM
From: Robert K.	Read Replies (2) of 17367

The cd-20 patent rights were considered at the time to be a "blocking" patent towards genentech/idec. I do believe that the company believed they gont fair money for it AT THAT TIME when money was critical. In hindsight, they regret selling it for so little, however IMO some of the Raptiva pluses may not have been possible had DNA got pissed off at xoma. skd FWIW- the new cd-20 molecules of dna>xoma has no rights to and that might even be more significant.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next